ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib-Reference-Cited by-同舟云学术

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib

Published:2020-05-20 Issue:6 Volume:38 Page:1687-1695
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Sakamoto Sho,Sato Kazuhiro,Takita Yuri,Izumiya Yuka,Kumagai Naho,Sudo Kazuhisa,Hasegawa Yukiyasu,Yokota Hayato,Akamine Yumiko,Okuda Yuji,Asano Mariko,Takeda Masahide,Sano Masaaki,Miura Masatomo,Nakayama Katsutoshi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-020-00946-x.pdf

Reference38 articles.

1. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A (2012 Sep) First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac OncolJ Thorac Oncol 7(9):1417–1422

2. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S (2009 Mar 20) Hagiwara K; north East Japan Gefitinib study group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin OncolJ Clin Oncol 27(9):1394–1400. https://doi.org/10.1200/JCO.2008.18.7658 Epub 2009 Feb 17

3. Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M, Tanimoto M, Kiura K (2013) Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 81:435–439

4. Igawa S, Sasaki J, Otani S, Ishihara M, Takakura A, Katagiri M, Masuda N (2015) Impact of smoking history on the efficacy of Gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations. Oncology 89:275–280

5. Miyazaki K, Sato S, Kodama T, Tamura T, Kagohashi K, Satoh H, Hizawa N (2016) Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer. MOLECULAR AND CLINICAL ONCOLOGY 4:873–877

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers;Xenobiotica;2023-12-12

3. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters;Nature Reviews Cancer;2023-09-15

4. Cannabis Pharmacogenomics: A Path to Personalized Medicine;Current Issues in Molecular Biology;2023-04-17

5. Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS;Journal of Pharmacological and Toxicological Methods;2023-03